Prof. dr. Lucija Peterlin Mašič is a full professor of Medicinal Chemistry and assistant professor of Toxicological Chemistry. She is internationally recognized expert in the field of Medicinal chemistry and Toxicology. She did a post-doctoral education in 2009 in AstraZeneca, Mölndal, Sweden, Safety Assessment Department in a group of Dr. Scott Boyer. She has more than 80 SCI publications, and she is the author of two US patents, more than 1350 citations (her h-index is 31 (Google Scholar)); she is organizer of several international meetings and member of the International Scientific Committee of ISMC (international Symposiums on Medicinal Chemistry) symposiums: ISMC Berlin 2012, ISMC Lisbon 2014, and ISMC Ljubljana 2018. She has been involved in three EU FP6 and 7 projects (FP6 INTAFAR, FP7 MAREX, INTEGRATE Marie Curie Educational Training Network (ETN)), and IMI Enable project. Her research activities are Structure and ligand based drug design; Design and synthesis of voltage-gated potassium ion channels modulators (Kv1.3 and hEAG1); Design and synthesis of novel antibacterial compounds (DNA Gyrase); Toxicological testing in the early drug discovery process; In vitro studies of drug metabolism; Testing compounds on nuclear receptors; Metabolism of xenobiotics and activity studies of their metabolites; and Bimolecular mechanism studies of toxicity.